Genetic engineering of T cells to express chimeric antigen receptors (CARs) is a promising new approach for adoptive immunotherapy of cancer. CARs are synthetic immune receptors that link antigen-binding domains, commonly single-chain variable fragments (scFvs), with T cell signaling domains to endow T cells with specificity for cell surface antigens independent of the major histocompatibility complex 1, 2 . Clinical trials have demonstrated impressive activity of CD19 CAR T cells against B cell malignancies [3] [4] [5] [6] [7] [8] [9] [10] . However, CARs targeting other antigens have thus far shown limited antitumor efficacy in clinical trials [11] [12] [13] [14] [15] [16] . Whether this reflects increased susceptibility of hematologic malignancies to this therapeutic approach, or superior functionality of the CD19 CAR constructs compared with CARs targeting other antigens, remains poorly understood.
It is well accepted that antitumor efficacy of adoptively transferred T cells requires efficient expansion and persistence in vivo [17] [18] [19] [20] , but there is currently little understanding of how CAR structure influences these properties. While developing CARs targeting the disialoganglioside GD2 on sarcoma, we found that some CAR T cells mediate potent in vitro cytolysis, but show limited expansion, persistence, and antitumor efficacy in immunodeficient xenograft models. T cell exhaustion is a major factor limiting antiviral and antitumor responses in the setting of chronic antigen exposure [21] [22] [23] [24] [25] [26] [27] [28] . Exhausted T cells have low proliferative and cytokine producing capacities, have high rates of apoptosis and express high levels of inhibitory receptors such as PD-1, TIM-3 and LAG- 3 (refs. 27,28) . Whether exhaustion has a significant role in limiting CAR efficacy, and how CAR structural design affects the development of exhaustion, has not been previously studied.
Here we demonstrate that early T cell exhaustion is a primary factor limiting the antitumor efficacy of CAR-expressing T cells and that CAR structure has a central role in predisposing CAR T cells to chronic activation and exhaustion. By dissecting the basis for differential in vivo activity between CD19 and GD2 CARs that show equivalent in vitro cytotoxicity, we found that antigenindependent signaling can drive early exhaustion in CAR T cells and limit antitumor efficacy in vivo. Furthermore, we demonstrate that tonic activation and exhaustion is not unique to the GD2 CAR, but is present to varying degrees in all CARs tested, except the highly effective CD19 CAR.
CARs commonly incorporate CD3-ζ and a costimulatory domain to provide both signals necessary for full activation of T cells. Although various costimulatory domains have been evaluated in preclinical studies, CD28 and 4-1BB have been most commonly tested in clinical trials 2 . Recent reports demonstrated significantly enhanced persistence of CD19 CARs incorporating the 4-1BB costimulatory domain compared with those including the CD28 domain 3, 4 . Using the GD2 CAR as a model for chronic CAR signaling, we additionally identify that the CD28 endodomain augments, whereas the 4-1BB endodomain ameliorates, key aspects of exhaustion, whether induced by antigen-independent signaling or induced by persistent exposure to antigen. Therefore, these data provide a biological basis for the differential in vivo persistence of CD19 CAR T cells with CD28 versus a r t i c l e s 5 8 2 VOLUME 21 | NUMBER 6 | JUNE 2015 nature medicine 4-1BB costimulatory endodomains in clinical trials 3, 4 , and are the first to identify anti-exhaustion effects associated with 4-1BB signaling.
RESULTS

GD2.28z CAR T cells have poor efficacy in vivo despite strong activity in vitro
In an attempt to develop CAR therapies for GD2-expressing solid tumors, we designed a second-generation, GD2-specific CAR incorporating the scFv derived from the 14g2a antibody 29, 30 plus the CD28 and CD3-ζ signaling domains (GD2.28z CAR; Supplementary Fig. 1 ).
The CH 2 CH 3 spacer domain of IgG 1 was incorporated to facilitate detection of CAR surface expression. T cells expressing the GD2.28z CAR efficiently lysed the GD2 + osteosarcoma line 143B in vitro, but failed to mediate antitumor effects in vivo in a xenograft mouse model ( Supplementary Fig. 2a,b) . A GD2.28z CAR without the spacer domain (GD2.sh.28z CAR) also showed no antitumor efficacy in vivo ( Supplementary Fig. 2c ), suggesting that poor activity was not due to activation-induced cell death triggered by the spacer domain 31 . A CD19-specific CAR with identical signaling domains 5, 32 (CD19.28z CAR; Supplementary Fig. 1a ) and comparable in vitro activity produced rapid and complete eradication of the CD19 + NALM6-GL leukemia in vivo ( Supplementary Fig. 2d ,e). This discrepancy led us to explore whether differences between in vivo efficacy of GD2.28z and CD19.28z CARs, despite similar in vitro cytotoxic capacities, were related to differential potencies of the CARs themselves or differential susceptibility of these tumors to T cell therapies.
To control for tumor-associated differences, we stably expressed CD19 on the 143B osteosarcoma cell line (143B-CD19; Fig. 1a) . In vitro cytolytic assays demonstrated that GD2.28z CAR and CD19.28z CAR T cells mediated comparable in vitro lysis of 143B-CD19 (Fig. 1b) . However, notable differences in antitumor efficacy were observed in vivo. GD2.28z CAR T cells had no effect on 143B-CD19 tumor growth rates, whereas CD19.28z CAR T cells induced regression of established 143B-CD19 tumors (Fig. 1c) . In mice treated with CD19.28z CAR T cells, tumors that eventually outgrew lacked CD19 expression (Supplementary Fig. 3a) , whereas in mice treated with GD2.28z CAR T cells, tumors that outgrew maintained GD2 expression (Supplementary Fig. 3b) . Furthermore, antitumor efficacy correlated with CAR T cell expansion and persistence in vivo. Although we readily identified CD19.28z CAR T cells in the spleen and tumor 14 d after adoptive transfer, GD2.28z CAR T cells were not found (Fig. 1d) . Despite equivalent in vitro cytolytic efficacy, CD19.28z CAR T cells persist and eradicate all detectable CD19 + tumor cells in vivo, whereas GD2.28z CAR T cells do not persist and do not inhibit tumor growth.
GD2.28z CAR T cells become exhausted during ex vivo expansion
We next sought to characterize GD2.28z versus CD19.28z CAR T cells during ex vivo expansion (Supplementary Fig. 4) . T cell activation levels were indistinguishable on day 4, but on days 5-7 GD2.28z CAR T cells began to show increased size, higher CD25 and 4-1BB expression, and lower CD27 and CD127 expression compared with CD19.28z CAR T cells or mock-transduced controls (Fig. 2a) . Despite increased activation, GD2.28z CAR T cells expanded less efficiently ex vivo (Fig. 2b) and showed higher rates of apoptosis (Fig. 2c) . By day 9, GD2.28z CAR T cells showed a cell surface and transcriptional profile consistent with exhaustion, including higher expression of PD-1, TIM-3 and LAG-3 ( Fig. 2d-f) , as well as the exhaustion-associated transcription factors T-bet and Blimp-1 ( Fig. 2g) 28, [33] [34] [35] . Furthermore, GD2.28z CAR T cells poorly produced interleukin 2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) compared with CD19.28z CAR T cells following exposure to 143B-CD19 cells (Fig. 2h) . We found no evidence that IL-2 added to the culture media substantially affected exhaustion, and this phenotype was not rescued with the addition of IL-7 to the culture medium (Supplementary Fig. 5 ). Together, these phenotypic, functional and transcriptional studies demonstrate that GD2.28z CAR T cells rapidly become exhausted during ex vivo culture, whereas similar effects do not occur in mock-transduced and CD19.28z CAR T cells stimulated in the same manner.
GD2.28z CAR has a dominant inhibitory effect on CAR T cell efficacy
To confirm that poor cytokine production by the GD2.28z CAR T cells resulted from T cell exhaustion rather than from differences in the potency of CAR-antigen interactions, we transduced T cells to express Fig. 6a ), yet produced lower amounts of IL-2, TNF-α and IFN-γ compared with T cells expressing the CD19.28z CAR alone when exposed to 143B-CD19 (Fig. 2h) and NALM6-GL cells (Supplementary Fig. 6b) . Therefore, the GD2.28z CAR exerts a dominant, inhibitory effect on the ability of T cells to produce cytokines in response to antigen.
In vivo experiments (Fig. 1c,d) were also repeated to include T cells transduced with both CD19.28z CAR and GD2.28z CAR (87% purity, Supplementary Fig. 6c ). A dominant, inhibitory effect of the GD2.28z CAR was also observed in vivo (Fig. 2i,j and Supplementary Fig. 3a ). These data demonstrate that the inferior activity of the GD2.28z CAR is not related to poor CAR-antigen interactions or impaired signaling upon exposure to antigen, but rather reflects exhaustion associated with expression of the GD2.28z CAR.
CAR signaling during ex vivo expansion leads to exhaustion
We next sought to identify the mechanisms that contribute to the in vitro exhaustion of GD2 CAR T cells. T cells bearing the CD19.28z CAR or the GD2.28z CAR were expanded ex vivo using anti-CD3/CD28 beads, but only the GD2.28z CAR T cells showed early exhaustion. We found no evidence that exposure to CD19 + B cells in the initial culture of peripheral blood mononuclear cells (PBMCs) protected CD19.28z CAR T cells from exhaustion ( Supplementary Fig. 7 ), leading us to hypothesize that signaling through the GD2.28z CAR itself had an essential role in inducing early exhaustion. To evaluate signaling of the GD2.28z and CD19.28z CARs, we probed CAR phosphorylation status via western blots with phospho-CD3-ζ specific antibodies. The GD2.28z CAR demonstrated basal levels of ζ-phosphorylation (Fig. 3a) , whereas the CD19.28z CAR showed ζ-phosphorylation only after crosslinking with an idiotype-specific antibody. These data demonstrate tonic signaling via the GD2.28z CAR during ex vivo expansion, and an absence of such signaling via the CD19.28z CAR.
To confirm an essential role for GD2.28z CAR signaling in the development of exhaustion, we knocked out GD2.28z CAR signaling via amino acid point mutations within the CD28 and CD3-ζ .mut-28. domains. Mutations were introduced in the SH2 and SH3 binding sites on CD28 that facilitate phosphoinositide 3-kinase (PI3K), lymphocyte-specific protein tyrosine kinase (LCK), growth factor receptor-bound protein 2 (GRB2) and GRB2-related adapter protein 2 (GADS) binding 36, 37 . Mutations were also introduced in the three immunoreceptor tyrosine-based activation motifs (ITAMs) required for CD3-ζ signaling via ZAP70 binding 38 (GD2.mut-28.mut-z CAR; Fig. 3b and Supplementary Fig. 1a) . T cells bearing the GD2.mut-28.mut-z CAR showed no signs of overactivation (Fig. 3c) and did not develop exhaustion (Fig. 3d) , despite equivalent cell surface expression levels compared with the wild type (WT) GD2.28z CAR (Supplementary Fig. 8 ). Furthermore, tonic CD19.28z CAR signaling induced by culturing T cells in the presence of a cross-linking idiotype-specific antibody replicated the exhaustion phenotype in CD19.28z CAR T cells in vitro (Fig. 3e-g ) and in vivo (Fig. 3h-j) . These data led us to propose that tonic signaling via the GD2.28z CAR results in early exhaustion.
Tonic GD2.28z CAR signaling is antigen independent
To identify factors responsible for tonic GD2.28z CAR signaling, we looked for the presence of GD2 in the culture system. Activated T cells expressed very low levels of the enzymes responsible for GD2 synthesis (36-fold less GD3 synthase and 205-fold less GD2 synthase than GD2 + tumor lines), and we could find no evidence for the surface expression of GD2 on activated T cells ( Supplementary Fig. 9a,b) . However, to rule out the possibility that low levels of surface GD2, soluble GD2 or another antigen that cross-reacted with the complementarity determining regions (CDR) were responsible for tonic GD2.28z CAR signaling, we introduced seven point mutations into the antigenbinding domain of the GD2.28z CAR to abrogate antigen binding (GD2.mutCDR.28z CAR; Supplementary Fig. 8b ). The GD2. mutCDR.28z CAR expressed efficiently on the T cell surface, but did not lyse GD2 positive tumors (Fig. 4a) , nor bind the 14g2a anti-idiotype antibody (1A7; Supplementary Fig. 8c ). Despite their inability to bind antigens, T cells expressing GD2.mutCDR.28z CAR continued to demonstrate early exhaustion (Fig. 4b) . We also synthesized a soluble version of the GD2 and CD19 scFvs to assess binding to cross-reactive antigens on the surface of activated T cells, but none were identified ( Supplementary  Fig. 9c ). We concluded that tonic signaling via the GD2.28z CAR was not due to GD2 or a cross-reactive antigen in the culture system.
Tonic GD2.28z CAR signaling is due to CAR clustering
The antigen independence of tonic GD2.28z CAR signaling suggested that structural components of the GD2.28z CAR, separate from the antigen-binding site, were responsible for the constitutive signaling. Given numerous studies describing scFv oligomerization in vitro [39] [40] [41] , we hypothesized that GD2.28z CAR scFv self-interactions may lead to receptor clustering and tonic signaling. Using CAR-fluorescent protein fusion constructs that retained functionality (Supplementary Fig. 10a ), we found that CD19.28z CARs are distributed uniformly across the T cell membrane, whereas GD2.28z CARs aggregate in punctae on the surface (Fig. 4c,d and Supplementary Fig. 10b) . Clustering was not due to an active capping process secondary to signaling through the CAR receptor, as GD2.mut-28.mut-z CAR T cells also demonstrated a punctate phenotype. Consistent with this, T cells transduced with both fluorescent CAR-Cerulean and CAR-Venus fusion proteins showed a higher intensity of Förster resonance energy transfer signaling in GD2.28z CAR T cells compared with CD19.28z CAR T cells (Supplementary Fig. 10c ). These data are consistent with a model in which tonic signaling of the GD2.28z CAR results from antigenindependent physical interactions between CAR receptors, leading to self-association and aggregation on the cell surface. Two structural elements, the linker and the spacer domain, were distinct between the CD19.28z and GD2.28z CARs; thus, we substituted the CD19 versions into the GD2.28z CAR to evaluate the impact on early exhaustion. Neither incorporation of the CD19 linker nor removal of the IgG 1 spacer domain (GD2.sh.28z CAR; Supplementary Fig. 1a and Supplementary Fig. 8d ) reduced CAR exhaustion (Fig. 4e,f) . In contrast, replacing the CD19.28z CAR scFv framework regions with those of the GD2.28z CAR scFv induced early exhaustion in the CD19.28z CAR (CD19-CDR.GD2-FW.28z CAR; Fig. 4g,h) . Although attempts were made to prevent exhaustion in the GD2.28z CAR by substitution of the CD19 scFv framework regions, CARs with this structure were not expressed on the T cell surface and hence could not be adequately evaluated. We concluded that framework regions within the 14g2a scFv are sufficient to induce tonic signaling, overactivation and early exhaustion in CAR T cells, which substantially limits antitumor efficacy.
Ex vivo exhaustion occurs to variable degrees in CAR T cells
To evaluate whether ex vivo exhaustion is a phenomenon unique to the GD2.28z CAR, we evaluated activation and exhaustion in T cells expressing three other CARs: two CARs specific for CD22 (ref. 20) (HA22 or m971 scFvs) and one CAR specific to ErbB2 (ref. 38) (4D5 scFv), all incorporating CD28-CD3-ζ signaling domains identical to the GD2.28z CAR (Supplementary Fig. 1b) . We observed varying degrees of activation following ex vivo culture, with the CD22-HA22.28z CAR T cells showing lower-level activation, whereas Fig. 11a) . The degree to which these cells showed increased activation during ex vivo culture correlated with an increase in expression of exhaustion markers ( Supplementary  Fig. 11b-d) and exhaustion-association transcription factors (Supplementary Fig. 11e ). We concluded that tonic activation leading to early exhaustion is likely present at varying degrees in most scFv-based CARs, except the CD19 CAR.
4-1BB endodomains ameliorate exhaustion of CAR T cells
Recent clinical trials have demonstrated differing persistence rates of CD19 CAR T cells incorporating CD28 versus 4-1BB costimulatory domains 3, 4 . Because exhausted T cells are known to persist poorly in vivo, we sought to evaluate whether the costimulatory domains influenced the development of exhaustion in the setting of chronic CAR signaling. Using the GD2 CAR as a model for chronic CAR signaling, we compared results in cells bearing the WT GD2.28z CAR (with both CD3-ζ and CD28) versus CARs capable of signaling via CD3-ζ alone and CD28 alone ( Supplementary Fig. 1a and Supplementary Fig. 8e ). These studies confirmed the essential role for CD3-ζ signaling in exhaustion (Supplementary Fig. 12 ). However, signaling through the WT receptor (which incorporates both CD3-ζ and CD28) led to higher expression of exhaustion markers and exhaustion-related transcription factors compared with signaling via CD3-ζ alone, suggesting that CD28 endodomains enhance exhaustion in this model system.
We next sought to investigate whether 4-1BB endodomains alter the development of exhaustion in this system by developing a GD2 CAR incorporating 4-1BB rather than CD28 (GD2.BBz CAR; Supplementary Fig. 1a and Supplementary Fig. 8f ). GD2.BBz CAR T cells showed similar levels of overactivation compared with GD2.28z CAR T cells (Fig. 5a) , whereas GD2.BBz CAR T cells expressed lower levels of exhaustion markers (Fig. 5b-d) , produced higher levels of cytokines (Fig. 5e) and mediated improved antitumor effects in vivo (Fig. 5f) . GD2.BBz CAR T cells also demonstrated increased persistence in vivo (Fig. 5g) and decreased exhaustion marker expression in vivo (Fig. 5h) . Similarly, we saw improved persistence and antitumor efficacy with CD22-m971.BBz CARs versus CD22-m971.28z CARs (Supplementary Fig. 1b and Supplementary Fig. 13 ), which also showed evidence of tonic activation during ex vivo expansion. Furthermore, 4-1BB ameliorates exhaustion with CD19 CARs, where we found improved persistence and decreased exhaustion marker expression of T cells in vivo after treatment of leukemic mice (Fig. 5i-j  and Supplementary Fig. 12c ). We concluded that CD28 endodomains augment exhaustion, whereas 4-1BB endodomains may provide an anti-exhaustion signal that can mitigate the adverse effects induced by chronic CAR signaling, whether by antigen-independent signaling or high tumor burdens.
4-1BB amelioration of exhaustion is associated with a unique transcriptional profile
We next sought to identify molecular pathways that contribute to the ameliorating effect of 4-1BB signaling on CAR T cell exhaustion. Global transcriptional profiles of nontransduced and CAR T cells from three donors were analyzed 9 d after initial in vitro activation Table 1 ). Principal component analysis demonstrated that despite donor variability, transcriptional profiles were clustered based on the CAR expressed (Fig. 6a) . T cells expressing CD19.28z and CD19.BBz CARs had global transcriptional profiles most similar to untransduced T cells, whereas T cells expressing the GD2.28z or GD2.BBz CARs had profiles distinct from untransduced and CD19 CAR T cells, and distinct from one another. Gene set enrichment analysis (GSEA) demonstrated that GD2.28z CAR T cells showed enrichment of genes previously identified as upregulated in exhausted T cells in mouse models 42 ( Supplementary  Fig. 14a) . Although some exhaustion-related genes were also upregulated in GD2.BBz CAR T cells (Supplementary Fig. 14b) , several key genes previously described to contribute to exhaustion 43 were differentially expressed between the GD2.28z and GD2.BBz CAR T cells (Fig. 6b) , and thus may contribute to the improved functionality of GD2.BBz CAR T cells. In particular GD2.28z CAR T cells showed higher expression of genes that encode inhibitory receptors, such as LAG3, HAVCR2 (TIM-3), CTLA4, BTLA and CD244 (2B4), and those that encode exhaustion-related transcription factors, such as TBX21 (T-bet), EOMES, PRDM1 (Blimp-1) and IKZF2 (Helios). GD2.BBz CAR T cells, in contrast, showed higher expression of genes that encode transcription factors reported to be associated with memory, such as KLF6, JUN and JUNB 43 . These results suggest that quantitative reductions in some exhaustion-associated molecules may contribute to the improved functionality observed in GD2.BBz CAR T cells.
We also conducted unbiased comparisons of GD2.28z versus GD2.BBz CAR T cells to identify pathways that might contribute to the improved functionality observed in GD2.BBz CAR T cells. GSEA with the Molecular Signatures Database 44 identified numerous gene sets enriched in GD2.BBz CAR T cells that are associated with response to hypoxia, including 32 gene sets from 16 publications related to hypoxia responses ( Fig. 6c and Supplementary Fig. 14c ). Other enriched gene sets included negative regulation of apoptosis/ programmed cell death and genes involved in regulation of cellular metabolism (Fig. 6c) . Additionally, we used a three-way comparison of the transcriptional profiles of GD2.28z, GD2.BBz and CD19.28z CAR T cells to identify genes uniquely dysregulated in GD2.28z CAR T cells, but normalized in GD2.BBz CAR T cells (Fig. 6d) . Similar to what was found in the GSEA analysis, many of the 34 genes identified were associated with hypoxia responses (EGLN3, EGR1, PTGIS, ID1), apoptosis (ID1), metabolism (GLUL, ATP10D, SMPDL3A), or T cell suppressive pathways (CTLA4, CD38, LGMN, CLECL1, ENTPD1, KLRC1/2). Our data suggest that 4-1BB ameliorates exhaustion in part by diminishing expression of known exhaustion-related genes, but it may also do so through modulating metabolism, apoptosis and/or response to hypoxia pathways.
DISCUSSION
Impressive early clinical results reported after administration of CD19 CAR T cells demonstrate the promise that CAR therapies hold as an immune-based treatment of cancer [3] [4] [5] [6] [7] [8] [9] [10] . However, so far this success has not been translated beyond CD19 + hematologic malignancies, and it remains unclear to what extent this relates to variable potencies of the chimeric receptors themselves. Here we provide the unexpected observation that GD2 CARs incorporating the scFv derived from the well-studied 14g2a antibody tonically signal during anti-CD3/CD28-based ex vivo expansion, which induces exhaustion in CAR T cells. This exhaustion seems indistinguishable from exhaustion occurring in non-engineered T cells in the setting of cancer and chronic viral infection [21] [22] [23] [24] [25] 27, 28 and is characterized by altered transcriptional profiles, high expression of exhaustion markers, poor proliferative capacity, poor cytokine production and poor antitumor efficacy in vivo.
The observation that some CARs tonically signal, leading to impaired T cell function and exhaustion, illustrates the importance of optimizing CAR engineering and a need for enhanced understanding of how receptor structure impacts function. Our work contributes to a growing literature demonstrating that structural characteristics of CAR ectodomains can critically affect functionality of these novel receptors 31, 45, 46 . Consistent with our results, a recent report by Frigault et al. identified that some CARs constitutively signal, which is associated with inferior in vivo efficacy 47 . Our results may explain this phenomenon by directly demonstrating CAR aggregation, CAR CD3-ζ domain phosphorylation, tonic T cell activation and ultimately T cell exhaustion. We further localize the cause of GD2 CAR clustering to interactions within the scFv framework regions. This is consistent with a sizable literature reporting that scFvs and other antibody fragments frequently oligomerize [39] [40] [41] , and raises the possibility that tonic signaling impacts the efficacy of many CARs incorporating other scFvs. Indeed, we observed substantial levels of antigen-independent activation and exhaustion across several different CARs.
Our results demonstrate that common in vitro cytotoxicity assays are likely to be insufficient to predict in vivo efficacy of CARs, as exhausted GD2.28z CAR T cells maintain cytolytic capacity in 51 Cr release assays, despite poor cytokine production and poor in vivo efficacy. This split functionality has been previously reported with exhausted T cells 28, 33, 48 . In CD107a degranulation assays, we detected preserved, yet notably lower, degranulation capacity of the GD2 CAR T cells compared with CD19 CAR T cells (Supplementary Fig. 10a) . Our results suggest that the ability of CAR T cells to be polyfunctional cytokine producers in response to antigen exposure may be a better predictor of CAR T cell antitumor efficacy in vivo.
Our evaluation of CAR T cell exhaustion was in the context of a tonically signaling CAR, although our results also have broader implications regarding potential mechanisms of CAR treatment failure. Exhaustion of tumor-reactive T cells is an increasingly wellestablished mechanism of immune evasion in cancer [21] [22] [23] [24] [25] [26] . CAR extrinsic factors such as high tumor burden are also likely to induce exhaustion and limit the efficacy of these effectors in vivo. Our data demonstrate that incorporation of 4-1BB in CAR design ameliorates the development of exhaustion in this setting and are consistent with reports that 4-1BB signaling can enhance T cell function in the setting of chronic viral infection 49, 50 . They also provide an explanation for recent reports demonstrating that CAR T cells incorporating the 4-1BB costimulatory domain have more prolonged persistence compared with those incorporating the CD28 costimulatory domain in clinical trials [3] [4] [5] 7, 9, 10, 51 .
The mechanisms that lead to exhaustion in the setting of tonic T cell signaling are complex and remain poorly understood. In an effort to better understand how 4-1BB signaling can ameliorate CAR T cell exhaustion, we compared the transcriptional profiles of GD2 CARs containing CD28 and 4-1BB costimulatory domains. In addition to diminished expression of known exhaustion-associated molecules in GD2.BBz compared with GD2.28z CAR T cells, we identified three pathways that are upregulated in GD2.BBz CAR T cells: response to hypoxia, cellular metabolism and negative regulation of apoptosis. Hypoxia-inducible factors have been recently reported to enhance effector T cell functions in the setting of chronic lymphocytic choriomeningitis virus (LCMV) infection 52 , and the ability of metabolism to influence T cell function and memory formation is becoming increasingly apparent [53] [54] [55] . To what extent these pathways npg contribute to the exhaustion-ameliorating effects of 4-1BB in CAR T cells is a focus of our ongoing studies.
In conclusion, our work implicates T cell exhaustion as a major factor limiting the efficacy of CAR therapies. The fact that CAR ectodomains can drive CAR T cell exhaustion, and that antigenindependent activation and exhaustion occur to varying degrees across a spectrum of CARs, highlights the importance of optimizing CAR engineering. This report also identifies 4-1BB as a potent mitigator of exhaustion in chronically stimulated CAR T cells, thus suggesting a basis for differential CAR T cell persistence observed in clinical trials using CARs with various costimulatory endodomains, and providing new insights into the biology of human T cell exhaustion.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. All generated microarray data are available at the Gene Expression Omnibus (GEO) with accession code GSE65856.
both the number of CAR + T cells and the total number of T cells remained consistent across CAR T cell groups.
Western blots. Whole cell lysates of CAR T cells were generated by lysing 5 × 10 6 washed cells in 150 µl of RIPA buffer (PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) with 1× Complete EDTA-free protease inhibitor (Roche) and 0.5 mM sodium vanadate (New England BioLabs), and then incubating for 30 min on ice. Samples were sonicated at 4 °C for 5 min to shear DNA. Western blots were then performed on supernatants of centrifuged samples, using an anti-CD3-ζ antibody (clone E-3, Santa Cruz Biotech) or an anti-pY142 CD3-ζ antibody (clone K25-407.69, BD Bioscience) primary and CleanBlot-IP Detection Reagent (Thermo Scientific) secondary. For analysis of T cells following receptor crosslinking, mock, CD19.28z CAR and GD2.28z CAR T cells were pre-incubated on ice for 10 min with OKT3, the 135.20.1 CD19 CAR anti-idiotype antibody, or the 1A7 GD2 CAR anti-idiotype antibody, respectively (10 µg/mL in PBS). Samples were washed and incubated for 5 min on ice with a crosslinking goat anti-mouse F(ab′) 2 (catalog number 115-006-071, Jackson ImmunoResearch; 25 µg/ml). Samples were then stimulated at 37 °C for 10 min, centrifuged and immediately lysed as above.
In vitro idiotype-mediated activation of CD19.28z CAR. The 135.20.1 CD19 CAR anti-idiotype antibody (0.25 µg/ml) and a crosslinking goat anti-mouse F(ab′) 2 (catalog number 115-006-071, Jackson ImmunoResearch; 2.5 µg/ml) were added directly to the culture media of CD19.28z CAR T cells, starting at the time of initial exposure to CD19.28z CAR retroviral supernatant (day 3). Idiotype and secondary were replenished every 2 d. Before flow cytometry, T cells were blocked in 10% normal mouse serum (Life Technologies), and then stained in the presence of 2% normal mouse serum.
Fluorescence microscopy imaging and analysis. T cells were transduced to express CAR-Cerulean fusion proteins. On day 9, CAR T cells were stained with the DiD membrane dye (Life Technologies) and with the LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Life Technologies) in PBS. Cells were washed, wetmounted, and images acquired with a Zeiss Apotome fitted with an AxioCam MRm camera, using a Zeiss Plan Apochromat 20× objective. Exposure settings were fixed at the beginning of acquisition and were unchanged for the duration of each experiment. Image analysis was performed using ImageJ. Dead cells were eliminated from analysis. The region of interest (ROI) for each cell, identified using the DiD membrane stain, was applied to the Cerulean (CFP) channel within which the dimensions of each region of interest and the maximum intensity projections were counted. Only a maximum intensity projection of greater than one was considered punctate (maximum intensity less than or equal to one was considered background). The threshold for the DiD stain was set at 10% of maximum pixel intensity. The threshold for the Cerulean channel was set at 20% of maximum pixel intensity.
Förster resonance energy transfer (FRET) analysis. T cells were transduced to express either only the Cerulean-or Venus-tagged versions, or transduced to express both the Cerulean-and Venus-tagged versions of the CARs. T cells were then flow sorted on day 7 (FACSAria II, BD Bioscience) to obtain pure CAR + populations with equivalent mean fluorescence intensities (MFIs) to normalize for CAR surface expression. CAR T cells were rested overnight in culture, then adhered to glass coverslips using CellTak (Corning), fixed in 4% paraformaldehyde for 5 min, and mounted using ProLong Gold (Life Technologies).
Images for FRET analyses were collected on a Yokogawa CSU-10 spinningdisk confocal microscope coupled to a Nikon TE-2000 using a Nikon 60× 1.4-NA objective. The illumination source for donor excitation was a 100-mW, 445-nm laser (Oxxius, Lannion, France; part number LBX-445-100-CIR-PP; 442-nm wavelength selected). The illumination source for acceptor excitation was a 150-mW, 514-nm Sapphire laser (Coherent, Inc., Santa Clara, CA; part number 1176578). Excitation power and wavelength control were provided by a Polychromatic acousto-optic modulator (Neos Technologies, Melbourne, FL; Model number 64040-75-.1-8CH-16B). The laser light was coupled into a single mode optical fiber and coupled to the Yokogawa spinning-disk unit. The excitation light was passed through a 445/514/561 multiband Yokogawa dichroic beamsplitter (Semrock, Lake Forest, IL; part number Di01-T445/515/561-13×15×0.5) to the objective. Emission light was reflected from the dichroic and passed through a 483/32 band-pass filter for donor emission (Semrock, Lake Forest, IL; part number FF01-483/32-25) and a 535/22 band-pass filter for acceptor emission (Semrock, Lake Forest, IL; part number FF01-535/22-25) mounted in a Lambda 10-2 optical filter changer (Sutter Instrument, Novato, CA). The fluorescence was detected using a CoolSNAP HQ2 CCD camera (Photometrics, Tucson, AZ). The microscope and components were controlled using the µManager open-source software 61 .
Three images were collected for each field of view: DD (donor-donor) images using 442-nm excitation while collecting 483/32 fluorescence, DA (donor-acceptor) image using 442-nm excitation while collecting 535/22 fluorescence, and AA (acceptor-acceptor) images using 514 -nm excitation while collecting 535/22 fluorescence. Sensitized acceptor emission FRET analysis was performed with the pFRET plug-in 62 in Fiji 63 , using quantum yields of 0.57 for Venus and 0.61 for Cerulean 64 and a 60% detector sensitivity in all channels. The FRET signal was measured in 100 to 150 cells, in one ROI per cell obtained by using a threshold for the uncorrected FRET images with the same value for all measurements.
Real-time PCR. mRNA was extracted from cells using the RNeasy Mini Kit (Qiagen) and reverse transcribed into cDNA using the SuperScript FirstStrand Synthesis System (Life Technologies). All reactions were performed with TaqMan Fast Universal PCR Master Mix (Applied Biosystems) on an Applied Biosystems StepOnePlus real-time PCR machine, using the following TaqMan primers (Applied Biosystems) with noted amplification factors (mean ± s.e.m.): GM2/GD2 synthase (B4GALNT1, Hs00155195_m1, 1.92 ± 0.01); GM1/GD1b/GA1 synthase (B3GALT4, Hs00534104_s1, 1.94 ± 0.04); GD3 synthase (ST8S1A1, Hs00268157_m1, 1.90 ± 0.02); T-bet (TBX21, Hs00203436_m1, 1.90 ± 0.02); Blimp-1 (PRDM1, Hs00153357_m1, 1.92 ± 0.01); β-actin (ACTB, Hs99999903_m1, 1.89 ± 0.02). Delta CT calculations were relative to β-actin and were corrected for PCR efficiencies.
Microarray, gene expression and GSEA analysis. RNA was extracted from cells using the RNeasy Mini Plus Kit (Qiagen). RNA was in vitro transcribed, fragmented and hybridized and applied to an Affymetrix Human Genome U133 Plus 2.0 array according to the manufacturer's instructions (Affymetrix) and in accordance with the microarray core facility of the National Cancer Institute (NCI) Frederick. Microarray data analyses were performed using Partek Genomics Suite Version 6.6. Data were uploaded using the original CEL z-scoring and normalized using the robust multichip average (RMA) algorithm. Differentially expressed genes were selected at ≥ twofold difference and P < 0.05. Cluster analyses and principal component analysis were conducted with Partek default settings. Heat maps were generated with expression data normalized to a mean of 0 and an s.d. of 1. GSEA analysis (http://www.broadinstitute.org/ gsea/index.jsp) was performed using default parameter settings. Published gene sets of gene ontology (MSigDB C5) and curated gene sets from the biomedical literature (MSigDB C2) were used for analysis 44 . Significance was defined as having a false discovery rate (FDR) <0.05.
In vivo studies. All animal studies were carried out under protocols approved by the NCI Bethesda Animal Care and Use Committee. Xenograft studies were performed using NSG mice (NOD.Cg-Prkdc scid ILrg tm1Wjl /SzJ, Jackson Laboratory) aged 6-12 weeks. Equivalent numbers of male and female mice were used. The 143B and 143B-CD19 osteosarcoma lines were inoculated at 5 × 10 5 or 10 6 cells periosteal to the tibia, and the NALM6-GL leukemia line was inoculated at 5 × 10 5 or 5 × 10 6 cells intravenously. Mice then received adoptive transfer of 10 7 transduced CAR T cells intravenously 3-14 d later, as indicated in individual experiments. Where indicated, mice also received 3 mg of cyclophosphamide (Millipore) intraperitoneally on day 2. To control for differences in transduction efficiency, untransduced T cells were supplemented to ensure that both the number of CAR + T cells and total number of T cells remained constant across CAR T cell groups. In osteosarcoma experiments, mice received cytokine support of 1 µg IL-7 (Cytheris Inc.) and 5 µg M25 antibody (anti-IL-7; Immunex) intraperitoneally three times per week after T cell transfer 65 . Osteosarcoma burden was quantified via two-dimensional leg area npg
